Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 34 Carcinoma, Non-Small-Cell Lung 26 Breast Neoplasms 25 Lung Neoplasms 24 Colonic Neoplasms 18 Head and Neck Neoplasms 16 Rectal Neoplasms 14 Sarcoma 10 Prostatic Neoplasms 10 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Neoplasms 7 Mouth Neoplasms 7 Melanoma 7 Esophageal Neoplasms 7 Ovarian Neoplasms 6 Glioblastoma 6 Adenomatous Polyposis Coli 6 Precancerous Conditions 5 Neuroblastoma 5 Liver Neoplasms 5 Central Nervous System Neoplasms 5 Carcinoma 5 Unspecified Adult Solid Tumor, Protocol Specific 4 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Oropharyngeal Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4

Interventions

Sirolimus 9 Everolimus 5 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphangioleiomyomatosis × Celecoxib × Clear all

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡